Skip to main content

Advertisement

SpringerLink
Log in

The link between serum neuregulin-1 and atherogenic index in type 2 diabetes mellitus

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Neuregulin-1(NRG-1) is a protein that belongs to the group of epidermal growth factors. It plays vital roles in anti-fibrotic effects on the myocardium. The current paper explores the role of NRG-1 in type 2 diabetes mellitus (T2DM) and its relation to atherogenic index as a factor for increasing cardiovascular disease(CVD) risk.

Material and methods

In this study, 79 diabetes mellitus patients are independent insulin. These patients consisted of 53 females and 26 males their age were ranged 40–67 years. They were divided into two groups depending on the atherogenic index of plasma (AIP). Group I including48 diabetic patient with high risk of CVD and group II including 31 diabetic patients without risk CVD. Forty healthy individuals were included as control.

Result

When compared to the control group, the serum levels of NRG-1 were significantly lower (p = 0.01). Additionally, group I had a much lower NRG-1level than group II. The results of multiple stepwise regression showed that the only independent predictor for NRG-1 level prediction was AIP (β =  − 0.600, P = 0.040). When comparing the diabetic patients with high risk factors for CVD to the healthy subject group, the AUC was outstanding (AUC = 0.889, P = 0.001) and had a high diagnosis.

Conclusions

We proved low NRG-1 levels in diabetic patients and the association of highest NRG-1 amounts to a better AIP. Moreover, the measurement of NRG-1 levels could be beneficial as laboratory markers to monitor for increasing CVD risk in type 2 diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abdulabbas DA, Hassan EA (2024) A case–control study to evaluate irisin levels in patients with type 1 diabetes mellitus. Ir J Med Sci (1971-) 13:1–8

    Google Scholar 

  2. Yadav JP, Patel DK, Pathak P, Grishina M (2022) Role of G-protein coupled receptor (GPCRs)/(GPR-120) as an agonists in diabetic wound healing. Obesity Medicine 1(36):100466

    Article  Google Scholar 

  3. Gebrie A, Sisay M, Gebru T (2020) Dyslipidemia in HIV/AIDS infected patients on follow up at referral hospitals of Northwest Ethiopia: a laboratory-based cross-sectional study. Obesity Medicine 1(18):100217

    Article  Google Scholar 

  4. Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557–1565

    Article  CAS  PubMed  Google Scholar 

  5. Zhu L, Lu Z, Zhu L et al (2015) Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. Kardiol Pol 73(10):931–938

    Article  PubMed  Google Scholar 

  6. Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34(7):583–588

    Article  CAS  PubMed  Google Scholar 

  7. Quispe R, Manalac RJ, Faridi KF et al (2015) Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 242(1):243–250

    Article  CAS  PubMed  Google Scholar 

  8. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka I (2010) Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 10(3)

  9. Fu L, Zhou Y, Sun J et al (2021) Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 20(1):201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Eldin AS, Fawzy O, Mahmoud E et al (2023) Serum neuregulin 1 in relation to ventricular function and subclinical atherosclerosis in type 2 diabetes patients. Endocrinología, Diabetes y Nutrición 70(10):619–627

    Article  PubMed  Google Scholar 

  11. American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl. 1):S81–S90

    Article  Google Scholar 

  12. Dobiásová M (2006) AIP–aterogenní index plazmy jako významný prediktor kardiovaskulárního rizika: od výzkumu do praxe [AIP–atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. Vnitr Lek. 52(1):64–71. Czech. PMID: 16526201.

    PubMed  Google Scholar 

  13. Flier, J,  Maratos-Flier, E. (2005). Obesity. In: Kasper DL Harrison’s principles of internal medicine, 16th ed. McGraw-Hill Companies 64:422–430

  14. Kadim BM, Hassan EA (2022) Nesfatin-1–as a diagnosis regulatory peptide in type 2 diabetes mellitus. J Diabetes Metab Disord 21(2):1369–1375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lefta RF, Hassan EA (2023) Serum soluble α-Klotho levels in patients with diabetic nephropathy. Irish Journal of Medical Science (1971-) 1–7

  16. Thomas D, Seeman T, Potter A et al (2018) HPLC-based measurement of glycated hemoglobin using dried blood spots collected under adverse field conditions. Biodemography Soc Biol 64(1):43–62

    Article  PubMed  PubMed Central  Google Scholar 

  17. Li Z, Huang Q, Sun L, Bao T, Dai Z (2018) Atherogenic index in type 2 diabetes and its relationship with chronic microvascular complications. Int J Endocrinol 2018:1

    Google Scholar 

  18. Prasad PS, Ganesh V (2018) Correlation of HbA1c with atherogenic index of plasma and endothelial dysfunction in type 2 diabetic subjects. International Journal of Clinical Biochemistry and Research 5(4):578–582

    Google Scholar 

  19. Yan P, Xu Y, Wan Q, Feng J, Li H, Yang J, Zhong H, Zhang Z (2018) Plasma neuregulin 4 levels are associated with metabolic syndrome in patients newly diagnosed with type 2 diabetes mellitus. Disease markers 2018

  20. Dai YN, Zhu ZJ, Fang ZY, Zhao DJ, Wan XY, Zhu ZT, Yu CH, Li YM (2015) A case-control study: association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism 64(12):1667–1673

    Article  CAS  PubMed  Google Scholar 

  21. Jiang J, Lin M, Xu Y et al (2016) Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults. Sci Rep 6(1):36710

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rahimzadeh M, Farshidi N, Naderi N et al (2020) Clinical significance of serum concentrations of neuregulin-4, in acute coronary syndrome. Sci Rep 10(1):5797

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29–34

    Article  CAS  PubMed  Google Scholar 

  24. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL (1991) Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?: the Rancho Bernardo Study. JAMA 265(5):627–631

    Article  CAS  PubMed  Google Scholar 

  25. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265(14):1861–1867

    Article  CAS  PubMed  Google Scholar 

  26. Manson JE, Colditz GA, Stampfer MJ et al (1991) A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151(6):1141–1147

    Article  CAS  PubMed  Google Scholar 

  27. Juutilainen A, Kortelainen S, Lehto S et al (2004) Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 27(12):2898–2904

    Article  PubMed  Google Scholar 

  28. Huxley R, Barzi F, Woodward M (2006) Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332(7533):73–78

    Article  PubMed  PubMed Central  Google Scholar 

  29. Geisberg CA, Wang G, Safa RN et al (2011) Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis 22(8):577–582

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ennequin G, Capel F, Caillaud K et al (2017) Neuregulin 1 improves complex 2-mediated mitochondrial respiration in skeletal muscle of healthy and diabetic mice. Sci Rep 7(1):1742

    Article  PubMed  PubMed Central  Google Scholar 

  31. Canto C, Pich S, Paz JC et al (2007) Neuregulins increase mitochondrial oxidative capacity and insulin sensitivity in skeletal muscle cells. Diabetes 56(9):2185–2193

    Article  CAS  PubMed  Google Scholar 

  32. Ennequin G, Boisseau N, Caillaud K et al (2015) Exercise training and return to a well-balanced diet activate the neuregulin 1/ErbB pathway in skeletal muscle of obese rats. J Physiol 593:2665–2677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cespedes JC, Liu M, Harbuzariu A et al (2018) Neuregulin in health and disease. Int J Brain Disord Treat 4(1):024

    PubMed  PubMed Central  Google Scholar 

  34. Shakeri H, Gevaert AB, Schrijvers DM et al (2018) Neuregulin-1 attenuates stress-induced vascular senescence. Cardiovasc Res 114(7):1041–1051

    Article  CAS  PubMed  Google Scholar 

  35. Bentzon JF, Otsuka F, Virmani R, Falk E (2014) Mechanisms of plaque formation and rupture. Circ Res 114(12):1852–1866

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran

    Wafaa Sh. Al–Zuhairi & Leila Sadeghi

  2. Department of Chemistry, College of Science, University of Diyala, Baquba, Diyala, Iraq

    Leila Sadeghi & Ekhlas Abdallah Hassan

Authors
  1. Wafaa Sh. Al–Zuhairi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leila Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ekhlas Abdallah Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leila Sadeghi.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al–Zuhairi, W.S., Sadeghi, L. & Hassan, E.A. The link between serum neuregulin-1 and atherogenic index in type 2 diabetes mellitus. Ir J Med Sci (2024). https://doi.org/10.1007/s11845-024-03711-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11845-024-03711-8

Keywords

Search

Navigation